Himmelfarb Health Sciences Library, The George Washington University

Health Sciences Research Commons
Obstetrics and Gynecology Faculty Publications

Obstetrics and Gynecology

3-2014

Long-term safety of ospemifene (52-week
extension) in the treatment of vulvar and vaginal
atrophy in hysterectomized postmenopausal
women
James A. Simon
George Washington University

David J. Portman
Columbus Center for Womens Health Research, Columbus, OH

R. Garn Mabey
The Ospemifene Study Group

Follow this and additional works at: http://hsrc.himmelfarb.gwu.edu/smhs_obgyn_facpubs
Part of the Obstetrics and Gynecology Commons
Recommended Citation
Simon, J., Portman, D., Mabey, R.G. et al. (2014). Long-term safety of ospemifene (52-week extension) in the treatment of vulvar and
vaginal atrophy in hysterectomized postmenopausal women. Maturitas, 77(3), 274-281.

This Journal Article is brought to you for free and open access by the Obstetrics and Gynecology at Health Sciences Research Commons. It has been
accepted for inclusion in Obstetrics and Gynecology Faculty Publications by an authorized administrator of Health Sciences Research Commons. For
more information, please contact hsrc@gwu.edu.

Maturitas 77 (2014) 274–281

Contents lists available at ScienceDirect

Maturitas
journal homepage: www.elsevier.com/locate/maturitas

Long-term safety of ospemifene (52-week extension) in the treatment
of vulvar and vaginal atrophy in hysterectomized postmenopausal
women夽
James Simon a,∗ , David Portman b , R. Garn Mabey Jr. c , the Ospemifene Study Group
a

The George Washington University School of Medicine, 1850 M Street NW, Suite 450, Washington, DC 20036, United States
Columbus Center for Women’s Health Research, 99 North Brice Road, Suite 120, Columbus, OH 43213, United States
c
Gynecology, 2881 North Tenaya Way, Las Vegas, NV 89128, United States
b

a r t i c l e

i n f o

Article history:
Received 26 November 2013
Received in revised form 4 December 2013
Accepted 7 December 2013
Keywords:
Dyspareunia
Ospemifene
Safety
Selective estrogen receptor modulator
Vaginal atrophy
Women without uterus

a b s t r a c t
Objective: To examine the long-term safety of oral ospemifene, a non-estrogen tissue-selective estrogen
agonist/antagonist, for the treatment of moderate to severe dyspareunia, a symptom of vulvar and vaginal
atrophy (VVA) due to menopause.
Study design: This multicenter, long-term, open-label, safety extension study was conducted in women
without a uterus aged 40–80 years (N = 301) who received oral ospemifene 60 mg/day for 52 weeks.
Participants either continued their 60-mg/day ospemifene dose from the initial 12-week pivotal efﬁcacy
study or switched from blinded placebo or ospemifene 30 mg/day to open-label ospemifene 60 mg/day.
The 52-week open-label extension period plus initial 12-week treatment period totaled up to 64 weeks
of ospemifene exposure. A 4-week posttreatment follow-up ensued (68 weeks total).
Main outcome measures: Safety assessments included adverse events, laboratory studies, physical and
gynecologic examination, vital signs, breast palpation, and mammography.
Results: Most treatment-emergent adverse events (TEAEs) during the extension study were mild or
moderate in severity. The most common TEAE related to study drug was hot ﬂushes (10%; leading to
discontinuation for 2% of patients). One serious TEAE, a non-ST-elevation myocardial infarction in a
patient with pre-existing cardiac disease, was considered possibly related to study medication. One mild
breast-related TEAE, considered unrelated to study drug, was ongoing at study completion. There were
no instances of pelvic organ prolapse, incontinence, venous thromboembolism, fractures, breast cancers
or death. No clinically signiﬁcant adverse changes were observed in other safety parameters.
Conclusions: Ospemifene is clinically safe and generally well tolerated in postmenopausal patients with
dyspareunia, a symptom of VVA.
© 2014 The Authors. Published by Elsevier Ireland Ltd. All rights reserved.

1. Introduction
Vulvar and vaginal atrophy (VVA) is a chronic and often progressive condition that affects approximately 50% of postmenopausal
women [1–5]. Despite the high prevalence of VVA, this condition is often undiagnosed or inadequately treated [1–3]. Currently
available treatment options include over-the-counter products
(lubricants and moisturizers) that may provide some temporary
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symptom relief, but do not treat the physiological changes underlying VVA, which can lead to the development of symptoms such as
dyspareunia [6–8]. Other treatment options include vaginal estrogen therapies, which are recommended to be used at the lowest
effective dose for the shortest duration consistent with treatment
goals and risks for the individual woman [4,9–12]. Given the limited
number of options, additional treatment choices for physicians and
patients are desirable [1,2].
Ospemifene, a tissue-selective estrogen agonist/antagonist (also
known as a selective estrogen receptor modulator, SERM), is the
ﬁrst non-estrogen oral prescription alternative to estrogen therapies for the treatment of moderate to severe dyspareunia, a
symptom of VVA due to menopause [13,14]. Ospemifene has multiple tissue-speciﬁc effects. Initial preclinical studies of ospemifene
on bone structure and strength demonstrated that ospemifene
has stimulatory effects on bone [15]. Additional preclinical studies showed that ospemifene treatment has anti-estrogenic effects
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in vitro and in vivo in human MCF-7 breast cancer cells [16,17].
To date, clinical trials on bone and breast endpoints have not
been performed. Ospemifene has neutral to antagonistic activity
on endometrial tissue [15]. The proﬁle of ospemifene in clinical
trials and in preclinical studies demonstrated beneﬁcial effects on
physiological changes in the vagina that are associated with VVA,
while having selective agonist/antagonist effects in other tissues,
and resulting in improvement of symptoms of dyspareunia in postmenopausal women [18,19].
In short- and long-term studies of postmenopausal women,
ospemifene was shown to be effective for the treatment of
moderate to severe symptoms associated with VVA [20–23]. In
a 12-week, randomized, double-blind study in postmenopausal
women (N = 826) comparing ospemifene 30 mg/day and 60 mg/day
with placebo, ospemifene 60 mg/day demonstrated statistically
signiﬁcant improvement over placebo for all co-primary endpoints,
including improvement from Baseline (“Baseline” refers to Day 1
of the initial 12-week study) in the percentages of superﬁcial and
parabasal cells (p < .001 for both), vaginal pH (p < .001), and severity
of the most bothersome symptoms of VVA, including dyspareunia
(p = .023) or dryness (p = .021) [20]. Ospemifene was generally well
tolerated. The most frequently reported adverse events (AEs) were
hot ﬂushes, which were generally mild or moderate in severity and
resulted in a low rate of discontinuation. Other commonly reported
AEs included urinary tract infections and headaches. In addition to
the 1-year safety extension study of ospemifene 60 mg reported
herein, a separate 40-week safety extension was conducted in a
cohort of women with an intact uterus (n = 180) who continued the
randomized double-blind treatment that they had been assigned
in the initial 12-week study (ospemifene 30 mg/day, ospemifene
60 mg/day, or placebo) [21].
During the extension period in the study of women with
an intact uterus, no clinically signiﬁcant adverse changes were
observed from safety assessments, which included endometrial
ultrasound and biopsy assessments; gynecologic examinations,
mammograms, and Papanicolaou tests; physical examinations;
vital signs; and safety laboratory values. Similar to the initial 12week study, the most frequently reported treatment-related AE
was hot ﬂushes, which resulted in few discontinuations. Since
several SERMs in development were associated with a signiﬁcant
4-fold or greater increased incidence of pelvic organ prolapse and
incontinence, treatment-emergent AEs (TEAEs) of this type are of
particular interest, especially in a hysterectomized cohort [24,25].
No increased incidences of prolapse or incontinence were observed
in hysterectomized women while taking ospemifene during this
extension study. This report presents ﬁndings from a 52-week,
open-label extension assessing the long-term safety of ospemifene
60 mg/day for the treatment of VVA in women without a
uterus.

2. Methods
2.1. Study design
This multicenter, open-label, long-term safety extension study
enrolled women without a uterus (ClinicalTrials.gov identiﬁer:
NCT01586364) who had participated in the initial 12-week, Phase
3, efﬁcacy and safety study of ospemifene for the treatment of
VVA in postmenopausal women (NCT00276094) [20] (Fig. 1A).
The details of this initial study have been described elsewhere;
however, a general summary is provided here. A randomized,
double-blind study of 826 postmenopausal women with and
without a uterus were randomized to receive ospemifene 30 or
60 mg/day or placebo (1:1:1) for 12 weeks. An additional, separate, long-term (52-week) extension study of women with a uterus
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has been completed and is described elsewhere [21]. This extension study included 301 women without a uterus. The duration
of the open-label treatment extension was 52 weeks. During this
extension, all patients were treated with ospemifene 60 mg/day
regardless of treatment assignment in the initial 12-week study.
The safety extension study concluded with a 4-week follow-up
period. Thus, the duration of treatment plus the posttreatment
follow-up period totaled 68 weeks (Fig. 1B).
The results of a separate long-term safety extension study
(NCT01585558) of 180 postmenopausal women with an intact
uterus, who completed the initial 12-week study and remained on
double-blind treatment with ospemifene or on placebo, have been
reported previously [21].
2.2. Patient population
All participants who entered the present open-label safety
extension study were required to have completed the initial 12week study. A detailed account of inclusion and exclusion criteria
for the initial study has been reported previously [20]. Brieﬂy,
the women were required to be 40–80 years of age and postmenopausal (deﬁned as at least 6 weeks elapsed since a bilateral
oophorectomy, or, in the case of hysterectomized women with
intact ovaries, follicle-stimulating hormone [FSH] levels ≥40 IU/L).
Participants were also required to have the following signs and
symptoms of VVA: ≤5% superﬁcial cells on a vaginal smear (Maturation Index); vaginal pH >5.0; and at least 1 moderate or severe
symptom of VVA (such as dyspareunia or vaginal dryness).
Exclusion criteria were as follows: body mass index (BMI)
≥37 kg/m2 ; systolic blood pressure ≥180 mm Hg or diastolic blood
pressure ≥100 mm Hg; clinically relevant abnormalities in safety
laboratory tests (hematology, chemistry, urinalysis, coagulation
parameters, serum lipid levels, and hormone levels) or electrocardiogram; clinically signiﬁcant abnormal ﬁndings on complete
pelvic examination, breast examination, or mammogram; suspicion or history of any malignancy within 10 years; or use of any
hormone therapy (unless a sufﬁcient washout period preceded any
procedure).
Women who met the study criteria and had completed the initial
12-week study were eligible for the present 52-week extension
study. Participants were excluded from the extension study if there
were clinically signiﬁcant abnormal ﬁndings at the Week 12 visit for
the initial study or if they had any physical or psychiatric condition
that could have interfered with their ability to adhere to the study
procedures.
Written informed consent, including agreement to follow dosing regimens and attend all study visits, was obtained prior to
enrollment. All participants received treatment with open-label,
oral ospemifene 60-mg tablets, which were taken once daily in
the morning with food. Institutional Review Board (IRB) approval
was obtained for each study site, with a central IRB responsible for
the initial and continuing review and approval of the clinical study
and for complying with the requirements of section 21 of the Code
of Federal Regulations (CFR), Part 56. The study was conducted in
accordance with the guidelines of Good Clinical Practice, the Declaration of Helsinki, and all applicable local regulations. This study
was conducted in accordance with the ethical principles originating
from the Declaration of Helsinki and current Good Clinical Practices
and in compliance with local regulatory requirements and 21 CFR
312.
2.3. Safety assessments
A summary of safety assessments is provided in Fig. 2. AEs
were documented at each study visit, and participants were
instructed to spontaneously report any AEs occurring between
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Fig. 1. (A) Study disposition (intent-to-treat population). a The number of participants without a uterus. b The number of participants with a uterus (reported separately) [21].
c
Lost to follow-up; participant decision/consent withdrawal; adverse event; major protocol violation; participant used a concomitant medicinal product that may compromise
safety or efﬁcacy evaluations; signiﬁcant noncompliance with treatment or study procedures; and any other reason as judged by the investigator. d One participant without a
uterus on ospemifene 30 mg/day signed an informed consent form but did not enroll in the extension study. e One participant without a uterus on ospemifene 60 mg/day was
moved to the extension study but did not sign an informed consent form and was not enrolled. f All participants without a uterus were treated with ospemifene 60 mg/day
(patients who had been randomized to receive ospemifene 30 mg or placebo in the initial 12-week study were switched to ospemifene 60 mg). (B) Timeline of the 52-week
safety extension of a 12-week efﬁcacy and safety study in postmenopausal women. a Patients in the extension study included only those without an intact uterus. b “Baseline”
in the 52-week extension study for safety and visual evaluation parameters refers to Baseline in the initial 12-week study. c Or discontinuation. d The total treatment period
for the safety study was 52 weeks, followed by a 4-week posttreatment follow-up period (68 weeks total, including the initial study).
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Fig. 2. Summary of assessments. a Papanicolaou smear was performed on women with an intact cervix at Week 52. BMI, body mass index.

visits throughout the study period. All AEs reported during the
study were considered TEAEs, deﬁned as any unfavorable event
(including laboratory value, symptom, or disease) associated with
the study drug or any other medicinal product taken by the participant. Signiﬁcant worsening in health status or existing diseases
observed during physical examinations were also considered AEs. A
treatment-emergent serious AE (TESAE) was deﬁned as any untoward medical event that resulted in death, was life threatening,
required inpatient hospitalization or prolonged an existing hospitalization, or resulted in persistent or signiﬁcant disability and/or
incapacity.
The clinical examinations used to evaluate safety included
physical examination and vital signs, breast palpation and mammograms, and gynecologic examinations. During visual examination
of the vagina, speciﬁc observations were made for vaginal dryness,
petechiae, pallor, friability, and redness of the mucosa. Each of these
vaginal assessments was rated on the following 4-point scale: 0,
none; 1, mild; 2, moderate; and 3, severe. Key laboratory assessments included serum lipid levels, hormone levels, and coagulation
parameters.
2.4. Statistical methods
The primary objective of this study was to assess the long-term
safety of 60-mg/day doses of ospemifene in the treatment of VVA in
postmenopausal women without a uterus. The analysis characterized changes from Baseline in safety parameters. (As noted earlier,
Baseline in the extension study refers to Baseline in the initial 12week study.) All analyses were performed using SAS® Release 8.2
(SAS Institute Inc, Cary, NC) and were conducted in the intentto-treat (ITT) population, deﬁned as all study participants who
received at least 1 dose of study medication. Descriptive statistics
were used unless otherwise noted. For continuous variables, data
were summarized, including the mean, standard deviation (SD),
median, and minimum and maximum values. Categorical variables
were summarized, including frequencies and percentages.
Demographic and Baseline characteristics were summarized
using all data available for each variable. The study parameters

were summarized using observed cases (OC) and the last observation carried forward (LOCF) method for available data at Week
26 ± 6 weeks and at Week 52 ± 6 weeks. Subjects were excluded
from summaries where data were missing for a given parameter.
AEs were coded by the Medical Dictionary for Regulatory Activities
(MedDRA) version 9.1 and tabulated by system organ class (SOC),
preferred term (PT), relationship to study drug, and severity. The
most frequently occurring AEs, serious AEs, and AEs leading to study
drug discontinuation were also summarized by SOC and PT.
3. Results
3.1. Participant disposition and demographics
A total of 379 participants who completed the initial 12-week
study had had a total hysterectomy and thus were eligible to enter
the safety extension study. For this investigation, 301 women were
enrolled and included in the ITT population. No details were collected on the 78 women who elected not to enroll. Of these 301
participants, 184 (61%) completed the ﬁnal treatment period (Week
52) of the extension (Fig. 1A). Baseline demographics and characteristics of the ITT population are shown in Table 1. The majority
Table 1
Demographic and Baseline clinical characteristics of the intent-to-treat population.a
Characteristic

Age (years), mean (SD)
BMI (kg/m2 ), mean (SD)
Race, n (%)
White
Black or African American
Asian
American Indian/Alaskan Native
Other

Ospemifene
60 mg/day
(N = 301)
59.4 (6.7)
26.9 (4.4)
278 (92.4)
11 (3.7)
6 (2.0)
3 (1.0)
3 (1.0)

BMI, body mass index; SD, standard deviation.
a
Demographic information was derived from the initial study of safety and efﬁcacy.
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Table 2
Summary of TEAEs during the 52-week extension study.
Event, n (%)

TEAE
Serious TEAE
Most frequent TEAEsc
Sinusitis
Urinary tract infection
Hot ﬂushes
TEAE leading to discontinuation

Table 3
Visual examination of the vagina in observed cases (OC)a .
Ospemifene
60 mg/day
(N = 301)a , b

Parameter, mean (±SD)

220 (73.1)
13 (4.3)
24 (8.0)
26 (8.6)
31 (10.3)
34 (11.3)

TEAE, treatment-emergent adverse event.
a
Does not include TEAEs that were ongoing from the 12-week pivotal study.
b
Includes participants in the intent-to-treat population.
c
Occurred in ≥5% of patients in any prior treatment group.

of participants were white (92.4%), the mean age was 59 years
(range, 41–80 years), and the mean BMI was 26.9 kg/m2 (range,
17.4–38.0 kg/m2 ).
Among the ITT population, the mean adherence rate to the study
drug was 86.7% and the mean duration of treatment was 309.2 days.
A total of 117 participants (38.9%) discontinued treatment, most
commonly because of withdrawal of consent (13.2%), followed by
an AE (12.3%) and lost to follow-up (5.6%) (Fig. 1A). See below reasons for discontinuation and refer to Table 2.
3.2. Safety and tolerability
3.2.1. Treatment-emergent adverse events
A summary of TEAEs that developed in the ITT population during the 52-week extension study is provided in Table 2. Of the
301 participants, 220 (73.1%) experienced at least 1 TEAE during
the extension study. Most TEAEs were rated mild or moderate in
severity, and the most frequently reported TEAEs were hot ﬂushes,
sinusitis, and urinary tract infection; among these, only hot ﬂushes
was study drug-related (Table 2).
A total of 19 TESAEs were experienced by 13 participants. Only 1
TESAE was considered by the investigators to be possibly related to
the study drug: a non-ST-elevation myocardial infarction in a 60year-old woman with pre-existing cardiac disease (requiring stent
placement 2.5 years before study enrollment) and a long history
of type 2 diabetes mellitus, hyperlipidemia, and hypertension. A
TESAE of hemorrhagic stroke, reported in 1 participant who completed the 12-week study on the 30-mg dose of ospemifene and
had entered the extension study, experienced the cerebrovascular
accident after 21 days on the 60-mg dose. The participant, who was
concomitantly receiving sumatriptan, recovered and the event was
considered by the investigator as unlikely related to ospemifene.
Thirty-four participants discontinued treatment due to a TEAE that
was not ongoing from the initial 12-week study. TEAEs that led to
discontinuation in ≥2 participants included hot ﬂushes (n = 6), nausea (n = 3), headache (n = 3), muscle spasms (n = 2), hyperhidrosis
(n = 2), and rash (n = 2). All 6 participants who discontinued due to
hot ﬂushes had entered the initial 12-week study with hot ﬂushes
at Baseline. There was 1 case of superﬁcial thrombophlebitis that
resolved after 1 day of heparin treatment, but there were no cases
of deep venous thromboembolism. There were no occurrences of
pelvic organ prolapse, incontinence, fractures, breast cancer, and
no deaths.
3.2.2. Clinical laboratory evaluations
No clinically signiﬁcant changes occurred from Baseline to Week
26 or Week 52 in the levels of total cholesterol, low-density
lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL)
cholesterol. Mean (±SD) total cholesterol declined from 213.2
(±38.2) mg/dL at Baseline to 208.3 (±32.8) mg/dL at Week 52;

Vaginal dryness in mucosa
Petechiae
Pallor
Friability
Vaginal redness in mucosa

Ospemifene 60 mg/day
Overall mean
change from BL
(initial study) to
Week 26
(extension study)
(N = 243)

Overall mean
change from BL
(initial study) to
Week 52
(extension study)
(N = 198)

−1.4 (±0.87)
−0.6 (±0.86)
−1.0 (±0.95)
−0.8 (±0.89)
−0.6 (±0.92)

−1.5 (±0.88)
−0.6 (±0.90)
−1.2 (±0.95)
−0.8 (±0.91)
−0.8 (±0.89)

BL, Baseline; SD, standard deviation.
Each characteristic was assessed on a 4-point scale: 0, none; 1, mild; 2, moderate;
and 3, severe.
a
Data collected from participants who discontinued the trial within 6 weeks of
the ﬁnal treatment visit (Week 52) were included in the OC analysis.

mean LDL cholesterol declined from 121.7 (±31.6) mg/dL to 116.1
(±27.0) mg/dL; and mean HDL cholesterol was virtually unchanged,
increasing slightly from 63.4 (±15.6) mg/dL to 63.8 (±16.7) mg/dL.
Mean triglycerides increased from 130.3 (±76.8) mg/dL to 135.5
(±65.3) mg/dL. A minor decrease in the mean ﬁbrinogen levels and a
minor increase in the mean protein-S antigen levels were observed
at Weeks 26 and 52. Overall, the mean levels of other coagulation parameters remained essentially unchanged, and no AEs were
reportedly related to coagulation parameters.
No clinically meaningful changes from Baseline in mean chemistry values were apparent at Week 26 or Week 52 using OC or
LOCF methodology. Among OC, the levels of FSH and luteinizing
hormone (LH) had decreased by Week 26 and Week 52, whereas
sex hormone-binding globulin (SHBG) and total testosterone had
increased, similar to the patterns of change observed in the initial
12-week study. The mean (±SD) changes from Baseline to Week
52 in FSH, LH, SHBG, and total testosterone were −15.9 (±13.6),
−1.7 (±6.7), 72.7 (±39.1), and 2.2 (±5.2), respectively. No major
changes were observed in mean estradiol (E2) or free testosterone
values; the majority of E2 values were below the limit of detection
(10 mg/mL).
3.2.3. Clinical signs and symptoms
No clinically signiﬁcant changes were observed in the mean
changes in vital signs at Weeks 26 or 52 of the extension study.
There were a total of 9 TEAEs categorized as being related to the
breast; however, only 4 were considered truly breast related, all of
which were considered mild or moderate in severity. One patient
in the ospemifene group had a breast-related TEAE (breast mass)
that was ongoing at the end of the study and at the 4-week followup (Visit 4). Further follow-up of this patient found that results
by mammography, conducted as part of routine care during the 5
years after study termination, were reported as normal. This AE was
assessed as mild and unlikely related to the study drug.
Efﬁcacy was assessed by visual examination of the vagina and
showed improvements from Baseline in the mean severity scores
for all 5 parameters (vaginal dryness, petechiae, pallor, friability,
and redness of the mucosa) at Weeks 26 and 52 of the extension
study (Table 3). Among participants assessed at Week 52, ≥93%
had scores of 0 (“none”) or 1 (“mild”) for all visual examination
parameters: vaginal dryness (93%), petechiae (96.5%), pallor (93%),
friability (97%), and redness of the mucosa (96%), with the greatest percentage improvement from Baseline in number of patients
scored as having “none” or “mild” for dryness by Week 52 (29.3%
vs. 93.0%, respectively) (Fig. 3).
The percentage of patients assessed as “severe” (score = 3) at
Baseline was 22.3% for vaginal dryness, 3.3% for petechiae, 13.3%
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Fig. 3. Visual evaluation of the vagina. Percentage of participants with a score of
0 (“none”) for each parameter, as assessed by visual evaluation of the vagina at
Baseline and at Week 52 (observed cases). Data collected from subjects who discontinued the trial within 6 weeks of the ﬁnal treatment visit (Week 52) were included
in the observed cases analysis. Examination scoring scale: 0, none; 1, mild; 2, moderate; and 3, severe. (Baseline: N = 300 patients on ospemifene 60 mg/day; Week 52:
N = 198 patients on ospemifene 60 mg/day.). The number in parentheses denotes the
number of subjects.
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indicated an increase of prolapse cases [24,29,30]. Raloxifene and
tamoxifen may have an effect on prolapse or urinary incontinence
but mixed results are reported [31]. The impact of SERMs on the
pelvic ﬂoor and other urogenital tissue is important, particularly for
women with hysterectomy given that hysterectomy may increase
the risk for prolapse and incontinence [32,33]. In this 52-week
extension study, no increased incidences of prolapse or incontinence were observed in hysterectomized women while taking
ospemifene.
Ospemifene has demonstrated a unique tissue-selective activity proﬁle suitable for its indicated use in postmenopausal women
with VVA. Although the current study focused on safety, visual
evaluations of the vagina showed sustained clinical improvements
(e.g., a 2-level change, from “severe” to “none,” “severe” to “mild,”
or “moderate” to “none”) from Baseline in all 5 characteristics
examined. Similarly, a greater percentage of patients at Week 52
compared to Baseline were assessed as having no ﬁnding of vaginal
dryness (67.7% vs. 2.3%), petechiae (77.8% vs. 40.7%), pallor (55.1%
vs. 9.3%), friability (85.4% vs. 37.3%), or redness of the mucosa (67.2%
vs. 20.0%), respectively. The clinical observations in the present trial
are consistent with results of the initial 12-week study and another
long-term safety study and further demonstrate pelvic ﬂoor safety
and a restoration of tissue quality and integrity in ospemifenetreated hysterectomized patients for up to 52 weeks [20,21]. The
open-label design of the current trial could be considered a limitation of the study results.
5. Conclusions

for pallor, 4.7% for friability, and 4.7% for redness of the mucosa; at
Week 52, the percentages were <0.5% for all parameters. Likewise,
the percentage of patients assessed as “none” (score = 0) increased
substantially between Baseline and Week 52 for all 5 parameters
assessed by visual examination of the vagina.
4. Discussion
In this safety extension study of postmenopausal women with
moderate to severe VVA who had previously undergone a hysterectomy, ospemifene 60 mg/day for up to 64 weeks was generally well
tolerated. Consistent with previous studies, most AEs were mild or
moderate in severity [20,21,23]. Although hot ﬂushes were among
the most common TEAEs in the extension study (observed in 10% of
women), they were associated with a low rate of discontinuation
(2%) and were experienced in participants with hot ﬂushes upon
entry into the initial 12-week study. Similar to ﬁndings in the 12week study and the long-term follow-up of women with an intact
uterus, there were no clinically signiﬁcant adverse changes in lipids,
coagulation parameters, or hormone levels among the women with
no uterus [20,21]. Any breast-related TEAEs were considered mild
or moderate in severity. The breast mass resolved in the ospemifene
recipient whose mass was present through the 4-week follow-up
period. Results of mammograms conducted as part of routine care
visits after conclusion of the study were normal.
The effect of SERMs on pelvic organs is not class speciﬁc and
each speciﬁc compound has different effects on the genitourinary tract. SERMs interact with both estrogen receptors ␣ and ␤
which are found throughout the urogenital tissue, including the
urethra, levator ani, and anterior vaginal wall, as well as in the
uterosacral ligaments [26–28]. The antagonistic effects of some
SERMs may impact the continence mechanism and pelvic support. Development of levomeloxifene for treatment and prevention
of osteoporosis was halted based on high incidence of adverse
effects including a 7% vs. 2% incidence of prolapse over placebo and
17% vs. 4% incidence of incontinence over placebo [25]. Likewise,
development of idoxifene was halted after preliminary observation

Once-daily treatment with ospemifene 60 mg was effective
and generally well tolerated in this long-term follow-up study of
postmenopausal women without a uterus. Safety ﬁndings from
this study are consistent with those of other Phase 3 studies in
women with an intact uterus. Most AEs were generally considered to be mild to moderate in severity. Visual evaluations of the
vagina showed sustained clinical improvement for all parameters
throughout the 52-week extension study with a greater percentage of patients assessed as having no symptoms compared with
Baseline. Additionally, no incidents of prolapse or incontinence
TEAEs were observed for this group of hysterectomized women.
Ospemifene, an estrogen agonist/antagonist with tissue-selective
effects, is the ﬁrst non-estrogen oral therapy suitable for its indicated use in the treatment of moderate to severe dyspareunia, a
symptom of VVA. At the 60-mg dose for 52–64 weeks, ospemifene
was safe and clinically effective in improving the symptoms of
vaginal dryness and dyspareunia associated with VVA for women
without a uterus.
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